18.28
price down icon0.87%   -0.16
after-market After Hours: 18.28
loading
Dyne Therapeutics Inc stock is traded at $18.28, with a volume of 913.11K. It is down -0.87% in the last 24 hours and down -7.72% over the past month. Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$18.44
Open:
$18.47
24h Volume:
913.11K
Relative Volume:
0.46
Market Cap:
$3.02B
Revenue:
-
Net Income/Loss:
$-446.21M
P/E Ratio:
-5.1589
EPS:
-3.5434
Net Cash Flow:
$-423.92M
1W Performance:
+4.22%
1M Performance:
-7.72%
6M Performance:
-2.71%
1Y Performance:
+56.24%
1-Day Range:
Value
$18.11
$18.84
1-Week Range:
Value
$17.32
$18.84
52-Week Range:
Value
$8.06
$25.00

Dyne Therapeutics Inc Stock (DYN) Company Profile

Name
Name
Dyne Therapeutics Inc
Name
Phone
(781) 786-8230
Name
Address
1560 TRAPELO ROAD, WALTHAM
Name
Employee
258
Name
Twitter
Name
Next Earnings Date
2026-05-14
Name
Latest SEC Filings
Name
DYN's Discussions on Twitter

Compare DYN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
DYN icon
DYN
Dyne Therapeutics Inc
18.28 3.05B 0 -446.21M -423.92M -3.5434
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
450.41 114.99B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
712.87 75.47B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
822.13 49.92B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
293.45 38.92B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
149.47 31.88B 742.00K -1.37B -1.07B -7.0731

Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-10-25 Upgrade Oppenheimer Perform → Outperform
Oct-10-25 Downgrade Oppenheimer Outperform → Perform
Aug-25-25 Upgrade Raymond James Outperform → Strong Buy
Jun-24-25 Initiated Bernstein Mkt Perform
Jun-11-25 Resumed Raymond James Outperform
Jun-02-25 Resumed Oppenheimer Outperform
May-29-25 Initiated Evercore ISI Outperform
Mar-12-25 Initiated BMO Capital Markets Outperform
Mar-07-25 Initiated Scotiabank Sector Outperform
Dec-13-24 Initiated Robert W. Baird Outperform
Nov-26-24 Initiated RBC Capital Mkts Outperform
Oct-24-24 Downgrade JP Morgan Overweight → Neutral
May-21-24 Reiterated Chardan Capital Markets Buy
Apr-30-24 Initiated Morgan Stanley Overweight
Feb-20-24 Initiated H.C. Wainwright Buy
Feb-27-23 Upgrade Raymond James Outperform → Strong Buy
Feb-15-23 Initiated Oppenheimer Outperform
Jan-26-23 Initiated Guggenheim Buy
Jul-20-22 Initiated Chardan Capital Markets Buy
Jul-12-22 Initiated Raymond James Outperform
Oct-12-20 Initiated JP Morgan Overweight
Oct-12-20 Initiated Jefferies Buy
Oct-12-20 Initiated Piper Sandler Overweight
Oct-12-20 Initiated Stifel Buy
View All

Dyne Therapeutics Inc Stock (DYN) Latest News

pulisher
04:14 AM

[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity - Stock Titan

04:14 AM
pulisher
04:05 AM

Dyne Therapeutics (DYN) CCO auto-sells shares to cover RSU taxes - Stock Titan

04:05 AM
pulisher
04:03 AM

Dyne Therapeutics (DYN) CFO logs automatic 1,448-share tax-related sale - Stock Titan

04:03 AM
pulisher
04:02 AM

Dyne Therapeutics (DYN) CEO’s 3,311-share sale is automatic tax withholding - Stock Titan

04:02 AM
pulisher
May 13, 2026

Dyne Therapeutics (DYN) upgraded to buy: Here's what you should know - MSN

May 13, 2026
pulisher
May 13, 2026

Form 144 filed on restricted stock units for DYN (NASDAQ: DYN) - Stock Titan

May 13, 2026
pulisher
May 13, 2026

DYN (Nasdaq) insider resale of 5,727 shares; 4,062 RSUs granted - Stock Titan

May 13, 2026
pulisher
May 13, 2026

Dyne Therapeutics to Participate in Upcoming Investor Conferences - Investing News Network

May 13, 2026
pulisher
May 13, 2026

Clinical-stage Dyne Therapeutics lines up three healthcare investor events - Stock Titan

May 13, 2026
pulisher
May 12, 2026

Responsive Playbooks and the DYN Inflection - Stock Traders Daily

May 12, 2026
pulisher
May 12, 2026

Dyne Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo

May 12, 2026
pulisher
May 12, 2026

DYN SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus

May 12, 2026
pulisher
May 11, 2026

Impact of FDA Leadership Changes on Dyne Therapeutics (DYN) - GuruFocus

May 11, 2026
pulisher
May 11, 2026

Dyne Therapeutics: Runway To Fund Operations Into 1Qf 2028 >DYN - Moomoo

May 11, 2026
pulisher
May 11, 2026

Dyne Therapeutics, Inc. Q1 2026 10-Q Report: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart

May 11, 2026
pulisher
May 11, 2026

Dyne Therapeutics (DYN) Advances Towards Z-Rostudirsen Launch in DMD - GuruFocus

May 11, 2026
pulisher
May 11, 2026

Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know - sharewise.com

May 11, 2026
pulisher
May 11, 2026

Dyne Therapeutics Q1 Net Loss Narrows - Moomoo

May 11, 2026
pulisher
May 11, 2026

Dyne Therapeutics Reports Positive Q1 2026 Results: Advancing DMD & DM1 Programs Toward FDA Approval and Commercial Launch - Minichart

May 11, 2026
pulisher
May 11, 2026

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights - Investing News Network

May 11, 2026
pulisher
May 11, 2026

Dyne Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

May 11, 2026
pulisher
May 11, 2026

Dyne Therapeutics 1Q Loss $120.9M >DYN - Moomoo

May 11, 2026
pulisher
May 11, 2026

Earnings Flash (DYN) Dyne Therapeutics Posts Q1 Loss $0.73 a Share, vs. FactSet Est of $0.74 Loss - marketscreener.com

May 11, 2026
pulisher
May 11, 2026

Dyne Therapeutics (NASDAQ: DYN) details DMD and DM1 trial progress - Stock Titan

May 11, 2026
pulisher
May 11, 2026

Dyne Therapeutics 1Q 2026: Net loss $(120.9M), EPS $(0.73) — 10-Q Summary - TradingView

May 11, 2026
pulisher
May 11, 2026

Dyne targets potential 2027-28 launches for two muscle drugs - Stock Titan

May 11, 2026
pulisher
May 11, 2026

Dyne Therapeutics (DYN) deepens R&D spend with $120.9M loss, $972M cash runway - Stock Titan

May 11, 2026
pulisher
May 11, 2026

MSN Money - MSN

May 11, 2026
pulisher
May 11, 2026

Number of shareholders of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView

May 11, 2026
pulisher
May 10, 2026

DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

May 10, 2026
pulisher
May 08, 2026

Changes Afoot at FDA: Impact on Dyne Therapeutics (DYN) - GuruFocus

May 08, 2026
pulisher
May 07, 2026

Dyne Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo

May 07, 2026
pulisher
May 06, 2026

Dyne therapeutics director Jason Rhodes sells $1.9m in shares By Investing.com - Investing.com India

May 06, 2026
pulisher
May 06, 2026

Dyne therapeutics director Jason Rhodes sells $1.9m in shares - Investing.com

May 06, 2026
pulisher
May 06, 2026

Atlas funds trim Dyne Therapeutics (DYN) stake in planned stock sales - Stock Titan

May 06, 2026
pulisher
May 06, 2026

[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan

May 06, 2026
pulisher
May 06, 2026

FMR LLC reports 5.4% stake in Dyne Therapeutics (NASDAQ: DYN) in Schedule 13G - Stock Titan

May 06, 2026

Dyne Therapeutics Inc Stock (DYN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$29.50
price up icon 0.96%
$91.99
price down icon 0.26%
$53.40
price up icon 0.28%
$115.62
price down icon 2.01%
ONC ONC
$304.62
price down icon 3.77%
$149.47
price down icon 0.31%
Cap:     |  Volume (24h):